AI Longevity Consortium at King’s College London The UK’s First Dedicated AI for Longevity Hub: Agenda for 2020 and Beyond
Longevity AI Consortium Overview ◆ The Longevity AI Consortium serves as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. The main concept of precision medicine is providing health care which is individually tailored on the basis of a person’s genes, lifestyle and environment. ◆ The Consortium will develop a comprehensive cloud computing platform to enable the development of “minimum viable” and “most comprehensive” panels of biomarkers of ageing , creating an ecosystem that incentivizes the participation of doctors, clinics, data providers, AI companies and corporate partners, and which enables efficient and streamlined commercialization and clinical implementation of both validated and experimental biomarkers of ageing as a framework for the extension of national Healthy Longevity in the UK.
Our Team and Advisors Dr. Alex Eric Kihlstrom Dr. Richard Siow Dmitry Kaminskiy Zhavoronkov Director at Ageing Chief Scientific Managing Trustee Director at Aging Research at King's Officer / at Biogerontology Analytics Agency / (ARK) AI Biomarkers of Research Former Interim Ageing Foundation / Director of the £98 Strategic Advisor million Healthy of Artificial Ageing Industrial Intelligence and Strategy Challenge Commercialisation Fund
Strategic Partners and Sponsors Aging Analytics Insilico Medicine Deep Knowledge Agency Ventures Biogerontology Longevity Research Foundation International
Longevity AI Consortium Investment Model Partners’ Network Core Capabilities Values and Importance 2020 launching a new decade Leading R&D hub and of AI and HealthTech for industry-academic hotspot Longevity R&D for advanced AI-driven personalized preventive diagnostics, prognostics and A comprehensive cloud therapeutics. computing platform to enable the development of “minimum viable” and “most comprehensive” panels of Global network of experts in biomarkers of ageing the areas of scientific R&D, business development and A synergetic and efficient investment relations. infrastructure spanning both industry, academia and the venture capital sector
Main Definitions ◆ Artificial Intelligence is the application of rapid data processing, machine learning, predictive analysis, and automation to simulate intelligent behavior and problem solving capabilities with machines and software. These processes include learning (the acquisition of information and rules for using the information), reasoning (using rules to reach approximate or definite conclusions) and self-correction. ◆ Longevity is defined as the number of years as a person could expect to live free from chronic age-related diseases and non-productivity if he or she were to pass through life subject to the age-specific mortality rates for a given period. Longevity specifically refers to the balance between the length of time someone lives and the quality of life in terms of the absence of disease.
Artificial Intelligence Technology Landscape Neuromorphic Autonomous Systems Computing Robotic Cyber Security Machine Learning Robotic Personal Deep Learning Assistance Autonomous Surgical Neural Networks Robotics AI Next Gen Cloud Pattern Recognition Robotics Thought Controlled Natural Language Gaming Processing Real Time Universal Chatbots Translation Real Time Emotion Virtual Companions Analytics
Longevity Industry Framework GEROSCIENCE R&D P4 MEDICINE Rejuvenation Personalized Personalized Gene Therapy Biotechnology Diagnostics Biomarker Analysis Regenerative Personalized Personalized in vivo & Geroprotectors Medicine Prognostics in silico drug testing Basic Research on Personalized QALY & Nutraceuticals Preventive Therapies Biology of Aging HALE Estimation AGETECH NOVEL FINANCIAL SYSTEM Novel Retirement Cognitive Longevity Hedge Longevity Index Fund Plans Enhancement Fund FinTech for the NextGen Mobile Longevity Stock AgeTech Bank Elderly Apps for the Elderly Exchange Entertainment for the Continuing Education Longevity Derivatives Longevity Trust Elderly
Ageing Research at King’s College London: Partnerships The Francis Crick King's Health Partners is The Healthy Ageing Institute is the new an Academic Health clinical theme at the national institute for Science Centre where Health Innovation biomedical research world-class research, Network is primarily focusing on new ways to education and clinical concerned with the diagnose, treat and practice are brought promotion of healthy prevent diseases. together for the benefit of living and the prevention patients. and management of illness and disability affecting older people.
Ageing Research at King’s College London: Partnerships The PLuS Alliance The ARK-TransCampus Science Gallery London combines the strengths partnership aims to connects art, science and of three leading stimulate, support and health to drive innovation universities Arizona State enable collaborations in in the heart of the city. University, King’s College fields of research within Science Gallery London is London and University of the ageing themes part of the Global Science New South Wales Sydney through academic Gallery Network, to contribute to a more exchange and sharing of connecting King’s just and sustainable resources to promote researchers to galleries future. knowledge transfer. worldwide.
Leveraging Unique Synergies in Academia, Industry and Finance Industry The Longevity AI Consortium serves as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. The main concept of precision medicine is providing health care which is individually tailored on the Cross-Sector basis of a person’s genes, lifestyle and Synergy environment. With the advances in genetics, artificial intelligence and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality. Academia Finance / VC
Artificial Intelligence: the Game Changer for Precision Health and Longevity Development of AI for Biomarkers of WealthTech and Ageing AgeTech Longevity AI for Novel Uses of AI for Longevity Longevity Life and Health R&D Data Financial Precision Wellness Health Third-Party Ecosystem AI for Continuous AI for Longevity Participants Biomarker Clinical Trials Monitoring
Primary R&D Goals for 2020 - End-to-End Healthy Longevity Research Development of personalised Identification of novel health, longevity and longevity and healthy treatment practices ageing biomarkers Major R&D Longevity-focused modulation Accelerated diagnosis of Focus and of sleep, nutrition, physical age-related health decline, Goals for activity and environmental with increased accuracy exposure 2020 Refining demographic and Developing AI-empowered clinical methods to solutions for financial facilitate recruitment, wellness across extended retention periods of healthy longevity
Core Areas of R&D: Full Scope Research Across Biomedicine, Tech and Finance R&D on AI for mental Niches where the science is ahead of Longevity clinical data, a health to optimize the funding: microbiome diagnostics comprehensive cloud psychological and therapeutics, recent innovations in computing platform, which wellness, social advanced cosmetics. enables efficient and activity, combat streamlined loneliness and social commercialization and isolation among clinical implementation of elderly. both validated and Longevity AI experimental biomarkers of ageing. Consortium Precision Health: AI-Driven Advanced Prognostics, A paradigm shift from Personalised treatment to prevention Treatment R&D on AI for Financial Wellness to and a new frontier - from Optimization, and maintain financial stability, social precision medicine to AI-Driven Preventative activity and psychological well-being precision health Treatment. across extended periods of Healthy Longevity.
Bridging Advanced R&D with Commercialization and Practical Implementation Advanced AI for Longevity R&D Bridging Research with Rapid Practical Spin Outs: Implementation Accelerator Turning Program: Research Supporting External into Startups Products
Building an Ecosystem for Academic - Industry - Public-Sector Synergy Development of Corporate Biomarkers of Partners Ageing AI Center for Longevity UK AI Center AI Companies NHS-X Trifecta AI Center AI for Medical Financial Centers Wellness Third-Party Ecosystem Corporate Doctors and Participants Partners Clinics
Priority Areas of the Longevity AI Consortium Frontier applications of artificial intelligence in ageing research, longevity R&D and the development of actionable biomarkers of health, ageing and longevity. The increasing shift toward actionable biomarkers of ageing, including the identification of biomarkers of health and longevity and that have the highest ratios of accuracy and precision vs. actionability, expense and ease-of-implementation, and the benchmarking of biomarkers that can be used in practice today to test the effectiveness of longevity therapeutics and lifestyle interventions.
Recommend
More recommend
